Armodafinil (Nuvigil), Postoperative Recovery of OSA (Obstructive Sleep Apnea) and Obese Patients
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
Obstructive sleep apnea (OSA) and obesity is associated with increased perioperative
morbidity and mortality. This group of patients is at risk of perioperative desaturations
which can be worsened by perioperative sedatives and narcotics needed for surgery. OSA
patients might also need to spend the night in intensive care for more frequent monitoring
for any desaturations episodes especially if the patient will be requiring multiple
intravenous narcotic boluses for pain control. Several studies have looked into the most
appropriate way to manage these patients and some recommendations have been made to avoid
outpatient surgery with close monitoring for first 24 hours after surgery specifically if
patient will require intravenous postoperative narcotics.
Nuvigil (Armodafinil) is a wake promoting agent (Cephalon inc., West Chester, PA) that's FDA
approved for excessive daytime sleepiness in narcolepsy, shift work sleep disorder, and
obstructive sleep apnea. The precise mechanism(s) through which armodafinil (R-enantiomer) or
modafinil (mixture of R- and S-enantiomers) promote wakefulness is unknown.
Nuvigil is longer acting product which is similar in action to Modafinil however is much
cheaper. Nuvigil has not been previously studied for postoperative recovery. The
investigators intend to study the effects of Nuvigil on postoperative recovery time and
wakefulness in obstructive sleep apnea and obese patients.